ALT5 Sigma (NASDAQ:ALTS) Lowered to “Strong Sell” Rating by Wall Street Zen

Wall Street Zen lowered shares of ALT5 Sigma (NASDAQ:ALTS) from a hold rating to a strong sell rating in a research report released on Saturday morning.

ALT5 Sigma Stock Performance

ALTS stock opened at $6.12 on Friday. ALT5 Sigma has a fifty-two week low of $1.55 and a fifty-two week high of $10.95. The company has a current ratio of 0.88, a quick ratio of 0.88 and a debt-to-equity ratio of 1.45. The business’s fifty day moving average price is $7.77 and its two-hundred day moving average price is $6.59.

Institutional Trading of ALT5 Sigma

Several hedge funds and other institutional investors have recently bought and sold shares of ALTS. Evernest Financial Advisors LLC acquired a new position in shares of ALT5 Sigma during the 2nd quarter worth approximately $87,000. Bridgeway Capital Management LLC boosted its stake in shares of ALT5 Sigma by 9.4% in the second quarter. Bridgeway Capital Management LLC now owns 19,339 shares of the company’s stock valued at $140,000 after buying an additional 1,661 shares during the period. Jane Street Group LLC bought a new stake in shares of ALT5 Sigma in the second quarter valued at approximately $380,000. Finally, Geode Capital Management LLC grew its position in ALT5 Sigma by 27.6% during the second quarter. Geode Capital Management LLC now owns 194,813 shares of the company’s stock worth $1,412,000 after buying an additional 42,157 shares in the last quarter. Institutional investors and hedge funds own 6.27% of the company’s stock.

About ALT5 Sigma

ALT5 Sigma Corp. is a clinical-stage biopharmaceutical company, which engages in identifying, acquiring, licensing, developing, partnering, and commercializing novel, non-opioid, and non-addictive therapies to address the large unmet medical need for the treatment of pain and addiction. It operates under the Biotechnology and Recycling segments.